Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank

Abstract Nuclear magnetic resonance (NMR)-based plasma fatty acids are objective biomarkers of many diseases. Herein, we aim to explore the associations of NMR-based plasma fatty acids with the risk of hepatocellular carcinoma (HCC) and chronic liver disease (CLD) mortality in 252,398 UK Biobank participants. Here we show plasma levels of n-3 poly-unsaturated fatty acids (PUFA) and n-6 PUFA are negatively associated with the risk of incident HCC HR Q4vsQ1 : 0.48 (95% CI: 0.33–0.69) and 0.48 (95% CI: 0.28–0.81), respectively and CLD mortality HR Q4vsQ1 : 0.21 (95% CI: 0.13–0.33) and 0.15 (95% CI: 0.08–0.30), respectively, whereas plasma levels of saturated fatty acids are positively associated with these outcomes HR Q4vsQ1 : 3.55 (95% CI: 2.25–5.61) for HCC and 6.34 (95% CI: 3.68–10.92) for CLD mortality. Furthermore, fibrosis stage significantly modifies the associations between PUFA and CLD mortality. This study contributes to the limited prospective evidence on the associations between plasma-specific fatty acids and end-stage liver outcomes.